Revolutionizing kidney care: The role of precision nephrology and artificial intelligence.

Tyron Harris*

Department of Nephrology, Harvard Medical School, USA

Introduction

Nephrology, the branch of medicine focused on kidney health, has undergone a significant transformation with the integration of Precision Medicine and Artificial Intelligence (AI). As chronic kidney disease (CKD) and other renal disorders continue to rise globally, innovative approaches are needed to improve diagnosis, treatment, and patient outcomes. Precision Nephrology, which tailors treatments based on an individual's genetic, environmental, and lifestyle factors, combined with AI-driven analytics, offers a promising future for kidney care [1].

Chronic kidney disease affects millions worldwide, often progressing silently until severe complications arise. Traditional nephrology relies on general guidelines that may not always account for individual variability. Precision Nephrology, however, seeks to customize treatment plans by leveraging patient-specific data, including genetic markers, metabolic profiles, and response to therapies. This personalized approach enhances treatment efficacy and reduces adverse effects, ultimately improving patient prognosis [2].

AI has revolutionized numerous medical fields, and nephrology is no exception. AI algorithms can process vast amounts of patient data to identify patterns and predict disease progression. Machine learning models help nephrologists make data-driven decisions, optimizing patient management strategies. AI-powered imaging and predictive analytics enable early detection of kidney abnormalities, facilitating timely intervention and reducing the risk of end-stage renal disease (ESRD) [3].

One of AI's most significant contributions to nephrology is early disease detection. AI algorithms analyze electronic health records, lab reports, and genetic data to identify individuals at high risk for CKD. Predictive modeling allows physicians to intervene before significant damage occurs, potentially slowing disease progression and improving patient outcomes [4].

Precision Nephrology, supported by AI, enables personalized treatment strategies. AI-driven drug discovery helps identify potential nephrotoxic effects of medications, ensuring safer prescriptions. Additionally, AI assists in determining the most effective dialysis or transplantation options by analyzing patient-specific factors, leading to better post-treatment outcomes [5].

AI plays a vital role in optimizing dialysis treatments. By analyzing historical patient data, AI can predict dialysis complications, such as fluid overload or hypotension, allowing clinicians to adjust treatment parameters accordingly. AI-powered wearable devices monitor patients' vital signs in real time, providing continuous feedback and reducing hospitalizations [6].

The integration of genomics in nephrology has opened new doors for identifying biomarkers linked to kidney diseases. AI algorithms analyze genomic data to uncover genetic predispositions to CKD, enabling targeted interventions. Biomarker-based diagnostics improve disease classification and guide clinicians in selecting the most effective treatment approaches [7].

AI-driven remote monitoring has enhanced nephrology care, particularly for patients with limited access to specialized clinics. Wearable devices and mobile health applications collect real-time patient data, enabling nephrologists to track kidney function and adjust treatment plans remotely. Telemedicine, powered by AI, facilitates virtual consultations, reducing the burden on healthcare facilities while ensuring continuous patient care [8].

Despite the advancements, AI-driven nephrology faces challenges, including data privacy concerns, algorithm biases, and the need for regulatory oversight. Ensuring the ethical use of AI in healthcare is paramount to prevent disparities in treatment access and quality. Continuous validation and transparency in AI models are crucial to gaining trust among healthcare professionals and patients [9].

The future of AI in nephrology is promising, with ongoing research focusing on deep learning models for kidney disease progression, AI-assisted robotic surgery for transplantation, and enhanced predictive analytics for personalized therapies. Collaboration between nephrologists, data scientists, and regulatory bodies will be essential in harnessing AI's full potential for kidney care [10].

Conclusion

The convergence of Precision Nephrology and Artificial Intelligence is revolutionizing kidney care by enabling early diagnosis, personalized treatments, and improved patient monitoring. AI-driven innovations are transforming nephrology into a more proactive, data-driven discipline,

***Correspondence to:** Tyron Harris, Department of Nephrology, Harvard Medical School, USA. E-mail: tyron@harris.edu

***Received:** 2-Feb-2025, Manuscript No. AACNT-25-161904; **Editor assigned:** 3-Feb-2025, PreQC No. AACNT-25-161904(PQ); **Reviewed:** 16-Feb-2025, QC No. AACNT-25-161904; **Revised:** 20-Feb-2025, Manuscript No. AACNT-25-161904(R); **Published:** 27-Feb-2025, DOI: 10.35841/aacnt-9.1.241*

***Citation:** Harris T. Revolutionizing kidney care: The role of precision nephrology and artificial intelligence. J Clini Nephrol. 2025; 9(1):241.*

significantly enhancing patient outcomes. While challenges remain, the integration of AI and precision medicine holds immense promise in combating kidney diseases and advancing nephrology toward a more personalized and efficient future.

References

1. Chapman AB, Devuyst O, Eckardt KU, et al. Autosomal-dominant polycystic kidney disease (ADPKD): Executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2015;88(1):17-27.
2. Yang X, Le Minh H, Cheng KT, et al. Renal compartment segmentation in DCE-MRI images. Med Image Anal. 2016;32:269-80.
3. Kistler AD, Poster D, Krauer F, et al. Increases in kidney volume in autosomal dominant polycystic kidney disease can be detected within 6 months.Kidney int. 2009;75(2):235-41.
4. Bhutani H, Smith V, Rahbari-Oskoui F, et al. A comparison of ultrasound and magnetic resonance imaging shows that kidney length predicts chronic kidney disease in autosomal dominant polycystic kidney disease. Kidney int. 2015;88(1):146-51.
5. Bhutani H, Smith V, Rahbari-Oskoui F, et al. A comparison of ultrasound and magnetic resonance imaging shows that kidney length predicts chronic kidney disease in autosomal dominant polycystic kidney disease. Kidney int. 2015;88(1):146-51.
6. Momeny M, Neshat AA, Hussain MA, et al . Learning-to-augment strategy using noisy and denoised data: Improving generalizability of deep CNN for the detection of COVID-19 in X-ray images. Comput Biol Med. 2021;136:104704.
7. Hohmann E. Editorial commentary: Big data and machine learning in medicine. J Arthrosc Relat Surg. 2022;38(3):848-9.
8. Sigmund M, Ferstl R. Panel vector autoregression in R with the package panelvar. Q Rev Econ Finance. 2021; 80:693-720.
9. Yang X, Le Minh H, Cheng KT, et al. Renal compartment segmentation in DCE-MRI images. Med Image Anal. 2016;32:269-80.
10. Cardenas CE, Yang J, Anderson BM, et al. Advances in auto-segmentation. Semin radiat oncol. 2019;29(3):185-197.

Citation: *Harris T. Revolutionizing kidney care: The role of precision nephrology and artificial intelligence. J Clini Nephrol. 2025; 9(1):241.*